Pandemic Preparedness: Managing Clinical Research During a Public Health Emergency

The unprecedented disruptions caused by the COVID-19 pandemic were felt across the drug development industry, triggering renewed interest from government, biotech and biopharma entities alike to invest in pandemic preparedness initiatives.

The PPD clinical research business of Thermo Fisher Scientific immediately recognized an industry-wide, unmet need to safeguard against future disruptions to the clinical development process and spearheaded the generation of a pandemic preparedness and rapid response delivery model. This program represents an executable action plan to deliver high-quality clinical data in the face of rapidly changing regulatory landscapes, compressed timelines and resourcing challenges.

The moderator and featured speakers will discuss how they integrated lessons learned from the COVID-19 pandemic into an operating manual to:

• Streamline feasibility and startup processes
• Build safeguards into bioprocess and manufacturing
• Leverage digital tools to enhance regulatory intelligence and the patient journey
• And more

Register for this webinar to learn what hurdles must be overcome while conducting effective clinical research in a pandemic scenario, and the advantages to having an established pandemic preparedness and rapid response model in place.